Literature DB >> 3408273

Polycystic ovarian disease: endocrinological parameters with specific reference to growth hormone and somatomedin-C.

W Urdl1.   

Abstract

Thirty-three women (22-38 years old) with polycystic ovarian disease (PCOD) were included in this study. The criteria for diagnosis were: an LH/FSH ratio greater than 2.0; polycystic ovaries, diagnosed by means of palpation and ultrasound; androgenism and menstrual cycle abnormalities. Using endocrine parameters, we attempted to define distinct forms of PCOD. The patients were placed in three groups according to serum levels of testosterone (T) and 17 alpha-hydroxyprogesterone (17 alpha OHP) and the estrone/androstendione (E1/delta 4A) ratio. Patients in group I (n = 18) had an elevated T level (greater than 1.0 ng/ml) and a 17 alpha OHP level under 4.0 ng/ml. This type of POCD was called the "androgen" type. Patients in group II (n = 7) had normal T- and 17 alpha OHP levels under 4.0 ng/ml and an elevated (E1/delta 4A) ratio. This type of PCOD was called the "estrogen" type. Group III (n = 8) comprised patients with 17 alpha OHP levels over 4.0 ng/ml. This type of PCOD was called the "adrenocortical" type. In two patients of this group, a modified ACTH test revealed late-onset congenital hyperplasia. The endocrine parameters of the patients with PCOD were compared with those of 17 adult without signs of PCOD. Statistical evaluation was done by variance analysis. Women with acromegaly often show signs of androgenism as well as menstrual cycle abnormalities. This may indicate an association between the growth factors human growth hormone (HGH) and somatomedin-C (Sm-C) and the biosynthese and metabolism of steroid hormone. Recent experiments have demonstrated such associations. Our study showed an association between the HGH and Sm-C levels and abnormal steroid hormone concentrations in women with androgen type PCOD (group I). These patients had a significantly decreased HGH level, a significantly decreased HGH/Sm-C ratio, and an increased average Sm-C level. These data suggest that elevated Sm-C levels can, by a negative-feedback mechanism, inhibit pituitary HGH production. We discuss the possible mechanisms causing elevation of plasma Sm-C, HGH, steroid hormones, excessive food intake, and possibly prolactin seem responsible for the clinical manifestation of increased Sm-C production in adolescence and for its level in the fertile years of patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3408273     DOI: 10.1007/bf00931548

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  133 in total

1.  Effect of spironolactone on sex hormones in man.

Authors:  B Stripp; A A Taylor; F C Bartter; J R Gillette; D L Loriaux; R Easley; R H Menard
Journal:  J Clin Endocrinol Metab       Date:  1975-10       Impact factor: 5.958

2.  CONCURRENT 3-BETA-HYDROXYSTEROID DEHYDROGENASE DEFICIENCY IN ADRENAL AND SCLEROCYSTIC OVARY.

Authors:  L R AXELROD; J W GOLDZIEHER; S D ROSS
Journal:  Acta Endocrinol (Copenh)       Date:  1965-03

3.  Characterization and development of cimetidine as a histamine H2-receptor antagonist.

Authors:  R W Brimblecombe; W A Duncan; G J Durant; J C Emmett; C R Ganellin; G B Leslie; M E Parsons
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

4.  The production, origin and role of dehydroepiandrosterone and delta 5-androstenediol as androgen prehormones in hirsute women.

Authors:  M A Kirschner; S Sinhamahapatra; I R Zucker; L Loriaux; E Nieschiag
Journal:  J Clin Endocrinol Metab       Date:  1973-08       Impact factor: 5.958

Review 5.  The insulin-like growth factors (IGF) of human serum: chemical and biological characterization and aspects of their possible physiological role.

Authors:  J Zapf; E R Froesch; R E Humbel
Journal:  Curr Top Cell Regul       Date:  1981

6.  Induction of immunoreactive somatomedin C human serum by growth hormone: dose-response relationships and effect on chromatographic profiles.

Authors:  K C Copeland; L E Underwood; J J Van Wyk
Journal:  J Clin Endocrinol Metab       Date:  1980-04       Impact factor: 5.958

7.  Changes in serum somatomedin and growth hormone concentrations after 3 weeks oestrogen substitution in post-menopausal women; a pilot study.

Authors:  S A Duursma; J W Bijlsma; H C Van Paassen; S C van Buul-Offers; A Skottner-Lundin
Journal:  Acta Endocrinol (Copenh)       Date:  1984-08

8.  Investigation of hirsutism: testosterone is not enough.

Authors:  G D Carter; S M Holland; J Alaghband-Zadeh; G Rayman; P Dorrington-Ward; P H Wise
Journal:  Ann Clin Biochem       Date:  1983-09       Impact factor: 2.057

9.  Hormone levels following wedge resection in polycystic ovary syndrome.

Authors:  V B Mahesh; S P Toledo; E Mattar
Journal:  Obstet Gynecol       Date:  1978-01       Impact factor: 7.661

10.  Secondary amenorrhea in obesity: etiologic role of weight-related androgen excess.

Authors:  A R Glass; W T Dahms; G Abraham; R L Atkinson; G A Bray; R S Swerdloff
Journal:  Fertil Steril       Date:  1978-08       Impact factor: 7.329

View more
  5 in total

Review 1.  Growth hormone cotreatment with gonadotropins in ovulation induction.

Authors:  P G Artini; A A de Micheroux; G D'Ambrogio
Journal:  J Endocrinol Invest       Date:  1996-12       Impact factor: 4.256

2.  [Growth factors, carbohydrate and lipid metabolism in females with polycystic ovary syndrome].

Authors:  W Urdl; G Desoye; B Schmon; H M Hofmann; W Hönigl
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

3.  Effects of ovary suppression by a long-acting GnRH-agonist on circulating GH, insulin-like growth factor I and insulin levels in women with polycystic ovary syndrome.

Authors:  G Tropeano; I Liberale; I P Vuolo; A Barini; G Caroli; P Carfagna; E Menini
Journal:  J Endocrinol Invest       Date:  1997-04       Impact factor: 4.256

4.  Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells.

Authors:  J F Cara; J Fan; J Azzarello; R L Rosenfield
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

5.  GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.

Authors:  F Orio; S Palomba; A Colao; T Russo; C Dentico; L Tauchmanovà; S Savastano; C Nappi; C Sultan; F Zullo; G Lombardi
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.